Welsh startup Amotio has raised £810,000 ($1.1m) to advance its technology for improving outcomes during orthopaedic revision surgery.
The company’s first major pre-seed funding round was led by a £500,000 ($682,000) investment from the Development Bank of Wales, with additional backing from European investment firm NLC Health Ventures and Orthopaedic Research UK.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Implant fixation takes the approach of uncemented fixation, where an implant is anchored to the bone, or cemented, where an implant is fixed using a compound made of Polymethyl Methacrylate (PMMA).
However, research from the UK indicates that around 7% of hip, knee, and shoulder implants require replacement due to issues such as implant failure, infection, loosening, or bone fractures.
Amotio worked with biomechanical engineers from University Medical Center Utrecht to develop a solution for removing bone cement during hip revision surgery. The technology uses advanced digital joint mapping, 3D printing, and precision tools. Starting with a patient’s CT scan, the system allows surgeons to collaborate with Amotio to create the surgical plan, including a custom-made guide and a specialised device for safe bone cement removal.
Through early-stage investment and non-dilutive funding, Amotio has now raised around £1.6m ($2.1m), which will support the company’s ongoing R&D and eventually help it progress to pre-clinical testing and regulatory approval for the technology.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAmotio’s eventual expectation is to expand its technology for use in all major joint surgeries for patients in global markets including the US, Europe, and the Asia-Pacific.
Amotio CEO Iestyn Foster commented: “In current financial conditions it is extremely difficult as a medtech start-up to attract initial early stage investment, but with the support of our co-founder and investor NLC Health Ventures, specialist venture funds from ORUK, and the Development Bank of Wales, they have all understood the complex needs of our business and the impact our solution will make, along with our ambitions for future growth.”
In the US, major joint replacement surgeries among those aged 50 and above are projected to reach five million by 2030.
